Search results for “Ilypsa”

Times Square Tower

document TEXT-001-HOUSE_OVERSIGHT_024003.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

… while maintaining board observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Ro...

Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction

document IMAGES-007-HOUSE_OVERSIGHT_024045.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

…t subsequently split to become 2 separate companies), Durata Therapeutics (NLV-II: IPO - July, 2012, NASDAQ: DRTX), and Ilypsa (Sprout IX, exited in sale to Amgen, 6.9x multiple). e Established Private Companies: The New Leaf Team has played the role of lead investor in a large...

molecular immunology at The Pasteur Institute and earned an M.D. and Ph.D. from the

document IMAGES-007-HOUSE_OVERSIGHT_024023.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

… while maintaining board observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Ro...

Sprout Capital IX, L.P. (Healthcare Technology Portfolio)

document IMAGES-007-HOUSE_OVERSIGHT_024102.txt Mar 31, 2014 House Oversight Committee — Epstein Estate Records (Nov 2025)

…Inc. Diagnostics & Infrastructure 2000 32.3 84.1 - 84.1 2.61 Gryphon Therapeutics Therapeutics 2002 13.3 0.2 - 0.2 0.01 Ilypsa, Inc. (fka Symyx) Therapeutics 2003 15.8 109.4 - 109.4 6.91 ISTA Pharmaceuticals, Inc. Therapeutics 2002 42.9 84.6 - 84.6 1.97 Kalypsys Therapeutics 2002...

Results for “Ilypsa”

Names that match “Ilypsa”